跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 5,501 条关于
“IgG-cleaving enzyme”
全部
5,501
临床试验
3,205
药物
574
机构
33
资讯
1,689
去年
Hansa Biopharma Appoints Dr. Richard Philipson as Chief Medical Officer to Lead Next Development Phase
去年
Hansa Biopharma's HNSA-5487 Shows Rapid IgG Reduction and Redosing Potential in Phase 1 Trial
11个月前
Hansa Biopharma Reports Positive Phase III ConfIdeS Trial Results for Highly Sensitized Kidney Transplant Patients
去年
Hansa Biopharma's Imlifidase Shows Promise in Guillain-Barré Syndrome and Anti-GBM Disease
去年
Hansa Biopharma's Imlifidase Shows Sustained Five-Year Outcomes in Kidney Transplant Recipients
去年
Imlifidase Shows Rapid Functional Recovery in Phase 2 Guillain-Barré Syndrome Trial
去年
Hansa Biopharma Secures $24.3M Funding as IDEFIRIX Sales Surge 76% in Q2 2025
去年
Novel IgG Degrading Enzyme KJ103 Shows Promising Safety and Efficacy in Phase I Trials
去年
Novel Enzyme Shows Promise in Treating IgG-Mediated Autoimmune Diseases
去年
Hansa Biopharma Completes Enrollment in Phase 3 Study of Imlifidase for Highly Sensitized Kidney Transplant Patients
第 1 页,共 169 页
上一页
下一页